Efficacy Analysis of Temozolomide in Treatment of Recurrent Brain Glioma

Objective To evaluate the efficacy and safety of temozolomide( TMZ) in the treatment of recurrent brain gliomas. Methods A total of 42 patients with recurrent brain glioma were treated by TMZ with a initial dosage of 150 mg /m2 once a day for durative 5 days and 28 days as a treatment cycle. The clinical curative effect and complications were observed after 3 cycles of treatment. Results The group of 42 patients was successfully completed chemotherapy,and no treatment-related death occurred during the therapy. There were 15 patients with reduced tumor sizes,and the partial remission( PR) rate was 35. 7%( 15 /42); 16 patients with stable diseases,and the stable disease( stable disease,SD) rate was 38. 1%( 16/42); 11 patients with tumor growth,and the progression( progressive disease,PD) rate was26.2%( 11/42). Efficiency rate( CR + PR) in the group was 35. 7%( 15 /42),and disease control rate( CR + PR + SD) was 73. 8%( 31 /42).Twenty-one patients had nausea and vomiting,and six patients had toxic reactions,such as decreased white blood cells,neutrophils,and platelets. Two patients showed different degrees of hair loss,but no damage of liver,kidney,and lung. Conclusion TMZ is an ideal chemotherapy drug that can be used to treat recurrent brain glioma,because it has a certain clinical effect and less adverse reaction.